For the quarter ending 2025-09-30, RNAC made $452K in revenue. -$35,912K in net income. Net profit margin of -7945.13%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 452 | 298 | 1,100 | 387 |
| Research and development | 13,802 | 14,869 | 14,674 | 11,400 |
| General and administrative | 7,716 | 7,240 | 8,315 | 6,562 |
| Total operating expenses | 21,518 | 22,109 | 22,989 | 17,962 |
| Operating loss | -21,066 | -21,811 | -21,889 | -17,575 |
| Interest income | 1,548 | 1,748 | 2,015 | 2,573 |
| Gain on change in fair value of warrant liabilities | -516 | -654 | -1,818 | -5,669 |
| (loss) gain on change in fair value of contingent value right liability | 16,900 | -35,300 | -346 | 15,100 |
| Loss on change in fair value of forward contract liabilities | 0 | 0 | - | - |
| Other income (expense), net | 0 | -5 | - | 250 |
| Net loss | -35,902 | 15,886 | -17,710 | -24,183 |
| Foreign currency translation adjustment | -10 | 12 | 32 | -15 |
| Total comprehensive loss | -35,912 | 15,898 | -17,678 | -24,198 |
| Basic (in dollars per share) | -1.38 | 0.51 | -0.68 | -1.13 |
| Basic (in shares) | 26,002,892 | 25,980,262 | 25,902,650 | 21,471,408 |
| Diluted (in dollars per share) | -1.38 | 0.5 | -0.68 | -1.13 |
| Diluted (in shares) | 26,002,892 | 26,447,251 | 25,902,650 | 21,471,408 |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)